Home
About Us
About
History
Organizers
Sponsors
Success Stories
Contestant Project Profiles
TiEQuest
Why Participate
Competition Prizes
TiEQuest Mentors
Panel of Judges
TiEQuest Team
Submissions
Competition Stages
Deadlines
Entry Criteria
Judging Criteria
Confidentiality
Resources
My Story
TiEQuest Handbook
Entry Form
Project Profile Form
Elevator Pitch
Business Plan
Presentations
TiE Institute
Calendar
News
What People Say
Contact Us
Blog
TiEQuest 2011 winner Rna Diagnostics receives investment from 4 angel groups!
TiEQuest 2011 winner Rna Diagnostics receives investment from 4 angel groups!
Four Angel Group Close Syndicated Life Science Investment with Rna Diagnostics Inc.
Toronto, Ontario, CANADA, March 14, 2012
York Angel Investors (YAI), announced today that an investment syndicate comprised of members of York Angels , the Golden Triangle Angle Network (GTAN), the Georgian Angel Network (GAN), and the Niagara Angel Network (NAN), has closed an investment in the amount of $ CDN 925,000 in Rna Diagnostics Inc. of Toronto Ontario.
“The investment in Rna Diagnostics is particularly significant, as the raise represents the collaborative efforts of members of four angel groups from across the province of Ontario,” said Rob Douglas, President of GTAN.
“We are pleased that we were contacted by Rna Diagnostics so early in their investment search and as such, we are today, very pleased to be involved with this very exciting and promising company. We would also like to thank Marc Castel of GTAN for his work in coordinating the investment process across the participating angel groups.” said Scott MacCannell, President of York Angel Investors Inc.
“We are delighted with the investment by the accredited Ontario Angel Investment Groups,” said Dr. Ken Pritzker, President and CEO of Rna Diagnostics Inc. "This funding will support the ongoing development of RDA a groundbreaking diagnostic test that will improve patient outcomes and reduce breast cancer treatment costs."
About Rna Diagnostics:
Rna Diagnostics Inc. (
www.rnadiagnostics.com
) is a molecular diagnostics company developing diagnostic tools to assist in the management of cancer chemotherapy. The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps oncologists to rapidly assess the effectiveness of cancer chemotherapy. RDA™ can determine whether chemotherapy is working effectively in the individual patient early in treatment thereby guiding clinical decision making.
« Back
Resources
TQ2012 launch overview
2011 TieQuest Manual
TiEQuest Success Stories 2010
Elements Of a Successful Business Plan
Important Dates
Intention to Participate, along with entry fee - Jan 31, 2013
Project Profile Due - Feb 3, 2013
Mentoring Workshop - Feb 21, 2013
Elevator Pitch - Mar 2,201
3
Upcoming Events
View All Events
Our Sponsors
JavaScript must be enabled in order for you to use BuiltCMS in standard view.However, it seems JavaScript is either disabled or not supported by your browser. To use standard view, enable JavaScript by changing your browser options.